Patent claim landscape of FDA Orange Book–listed oral oncology drugs: A systematic analysis of standard practice claims.

e23042 Background: Patents listed in the FDA Orange Book influence the timing of generic drug entry. While intended to protect innovation, Orange Book patents increasingly include secondary claims related to dosing, administration, and treatment use that may overlap with routine oncology practice. We systematically evaluated the scope and clinical relevance of Orange Book patent claims for oral small-molecule oncology drugs using a clinical “person of ordinary skill in the art” (POSITA) framework. Methods: We conducted a cross-sectional analysis of all oral small-molecule oncology drugs listed in the FDA Orange Book as of December 2024. Patents were retrieved from USPTO and Google Patents databases. Claims were manually extracted and categorized using a 16-category framework reflecting common oncology decision points and common claim descriptions. Claim sets (independent claim plus dependents) were the unit of analysis. Patent portfolio characteristics, claim co-occurrence, and references to human clinical evidence were analyzed descriptively. Results: Seventy-eight drugs were associated with 543 Orange Book patents comprising 10,311 claims and 1,514 claim sets. Clinically oriented claim categories were common, including therapeutic indication (39%), route of administration (32%), listed dose (28%), and implicit dosing or dose modification (25%). Overall, 58% of claim sets contained at least one element categorized as routine clinical practice, compared with 21% containing claims considered potentially less likely routine (e.g., biomarker-based selection). Co-occurrence analysis showed frequent bundling of standard-practice elements, including dose with formulation (Jaccard index 0.51) and timing with treatment line (0.40). Only 23% of patents referenced any human clinical data; among these, 68% cited Phase I or observational evidence only, and 16% referenced Phase III trials. Drugs with larger and more diverse patent portfolios had longer effective protection durations (Spearman ρ ≈ 0.42, p < 0.01). Conclusions: Orange Book patents for oral oncology drugs frequently include claims overlapping with routine clinical practice, often supported by limited clinical evidence. Bundling of standard-practice claims is common and associated with prolonged protection timelines, raising questions about the alignment between patent scope, clinical innovation, and generic access as it relates to Orange Book listings.